“Speaking truth to power”
- a Quaker maxim.
 
Top News arrow News / Infomails
News and Infomails from AHRP
Placebo Beat Both Zyprexa & Eli Lilly's Experimental Drug Print E-mail
Tuesday, 14 April 2009
The results suggest that the truth may have escaped the usual exclusion criteria. Underlying the commercial success of the new antipsychotics is evidence (usually suppressed) showing that these drugs are both harmful and ineffective even for their approved use.
Read more...
 
Pfizer Settles Nigerian children Deaths-- $75 Million Print E-mail
Monday, 13 April 2009
"The strategy of big companies when they are dealing with smaller opponents is to stretch the process, to overwhelm us until we are ready to accept whatever they want to offer."
Read more...
 
"Doctors of Deception" Electroshock machines to Undergo safety & efficacy tests Print E-mail
Monday, 13 April 2009
It may come as a shock to some of you; but, Electroshock machines have never been tested for safety or efficacy.
Read more...
 
Harvard-Partners Hospitals Curtail Industry-Doctor $$ Perks Print E-mail
Saturday, 11 April 2009
Dr. Peter Slavin, president of Mass. General Hospital: "We don't want our faculty being on the road as hired guns."
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Results 239 - 252 of 753
(C) 2012 Alliance for Human Research Protection
CMS installation and website development by Anne Krauss

General Terms & Disclaimer:

This site is not a monologue of truth. It is a catalyst for public debate about medical research conduct. The reader is urged to confront officials to clarify issues mentioned herein. This site is designed strictly to provide information for critical, literary, academic an public usage. A qualified and trustworthy medical professional must be consulted regarding medical issues, treatments, diagnoses, etc.

Please read the General Terms and Conditions of this agreement entirely and carefully before accessing this web site. By accessing the site, you agree to be bound by the terms and conditions listed herein. [continue]